Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA

September 28, 2020 -- Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that it received a rare pediatric disease (RPD) designation from the United States (US)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials